| Literature DB >> 33488575 |
Deenadayalan Bakthavatsalam1, John W Craft1,2, Anna Kazansky1, Nghi Nguyen3, Goeun Bae3, Amy R Caivano1, C William Gundlach1, Asra Aslam2, Safa Ali2, Shashikant Gupta1, Sophie Y Lin1, Hema D Parthiban1, Peter Vanderslice1, Clifford C Stephan3, Darren G Woodside1.
Abstract
Leukocyte inflammatory responses require integrin cell-adhesion molecule signaling through spleen tyrosine kinase (Syk), a non-receptor kinase that binds directly to integrin β-chain cytoplasmic domains. Here, we developed a high-throughput screen to identify small molecule inhibitors of the Syk-integrin cytoplasmic domain interactions. Screening small molecule compound libraries identified the β-lactam antibiotics cefsulodin and ceftazidime, which inhibited integrin β-subunit cytoplasmic domain binding to the tandem SH2 domains of Syk (IC50 range, 1.02-4.9 µM). Modeling suggested antagonist binding to Syk outside the pITAM binding site. Ceftazidime inhibited integrin signaling via Syk, including inhibition of adhesion-dependent upregulation of interleukin-1β and monocyte chemoattractant protein-1, but did not inhibit ITAM-dependent phosphorylation of Syk mediated by FcγRI signaling. Our results demonstrate a novel means to target Syk independent of its kinase and pITAM binding sites such that integrin signaling via this kinase is abrogated but ITAM-dependent signaling remains intact. As integrin signaling through Syk is essential for leukocyte activation, this may represent a novel approach to target inflammation.Entities:
Keywords: cell adhesion; high-throughput screening; immune response receptor; inflammation; integrin; signaling; tyrosine kinase; β-lactam antibiotics
Mesh:
Substances:
Year: 2021 PMID: 33488575 PMCID: PMC7819857 DOI: 10.3389/fimmu.2020.575085
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561